The facility is spread across 12 acres and has a capacity of about 197 KL, the company said.
The plant was inspected by the USFDA in 2015, it added.
“These were much needed to provide flexibility to our operations in the near term and more importantly to meet our growth aspirations over next few years,” said Sucheth Davaluri, Vice Chairman and CEO of Neuland.
The factory makes multiple products and has five production blocks for advance intermediate and API manufacturing.
It also has capabilities for on-site development, analytical method development, quality control laboratory and a pilot plant, the company said.
Neuland Laboratories has been manufacturing active pharmaceutical ingredients (drugs) for over 33 years.
It currently has customers in close to 80 countries.